Biobank of Samples From Patients With Infectious Diseases (INFECTIOTEK)

Assistance Publique - Hôpitaux de Paris

Status: Not yet enrolling

Conditions: Infectious Diseases

Treatments: Other: Sampling

Study type: Observational

Funder types: Other

Identifiers

NCT06722131

APHP240413

Details and patient eligibility

About

The aim of the INFECTIOTEK biobank will be to prospectively build a biobank of multiple biological samples from patients with infectious diseases in order to identify diagnostic and prognostic biomarkers, genetic susceptibility factors and immune response mechanisms in such diseases.

The population of the study will consist of patients treated in the Infectious Diseases Departments of Saint-Louis and Lariboisière Hospitals, with a diagnosis of infectious disease, and who have biological samples in the context of their routine medical care.

The diseases studied in this research project are bacterial infections (urinary tract infections, neurologic infections, sexually transmitted infections, pulmonary infections), viral infections (HIV, hepatitis, respiratory viruses, viruses affecting immunocompromised patients) and fungal infections (Aspergillus, Mucorales, Cryptococcus). These diseases are the domains of expertise and research of the clinical and biological teams at the Saint-Louis and Lariboisière hospitals.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient over 18 years of age

• Diagnosed with one of the following infectious diseases :

  • Infection with HIV-1 or HIV-2, or person at risk of infection with HIV
  • Viral hepatitis (HAV, HBV, HCV, HDV, HEV)
  • Pulmonary infections: bacterial (notably Nocardia), viral (Influenza, RSV, SARS-CoV-2, Adenovirus), fungal (Aspergillus, Mucorales)
  • Urinary tract infections
  • Sexually transmitted infections (Neisseria gonorrheae, Chlamydia trachomatis, Mycoplasma genitalium, Treponema pallidum)
  • Neuromeningeal infections: (Neisseria meningitidis, Streptococcus pneumoniae), viral (HSV, VZV), fungal (Cryptococcus).
  • Infections affecting immunocompromised patients: herpes viruses (HSV, VZV, CMV, EBV), polyomavirus BK
  • Emerging pathogen X (in the event of an epidemic)
  • Signature of research consent form
  • Health coverage with social security system or state medical aid

Exclusion criteria

• Refusal to participate
• Inability to give consent (cognitive impairment etc...)

Trial design

1,000 participants in 1 patient group

Patients diagnosed with an infectious disease

Treatment:

Other: Sampling